ArticleNature communications2016
An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques.
Abstract read
In one paragraph
Article in Nature communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 268 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
268citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
268 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sex Differences in Omega-3 and Omega-6 PUFA Status: A Systematic Review and Meta-analysis of Cross-Sectional Comparisons.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Trial
- Plasma Resolvin D2 to Leukotriene BBioMed research international · 2021Trial
- Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain.Journal of translational medicine · 2020Trial
- Imbalanced serum levels of resolvin E1 (RvE1) and leukotriene B4 (LTB4) in patients with allergic rhinitis.Molecular biology reports · 2020Trial
- Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease.Journal of the American Heart Association · 2020Trial
- Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Trial
- Efferocytosis activates a DNMT3A-mediated oxidized DNA repair pathway to enable tissue resolution.The Journal of clinical investigation · 2026Article
- Resolving the links between efferocytosis and DNMT3A mutation-driven clonal hematopoiesis in atherosclerosis.The Journal of clinical investigation · 2026Article
- Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution inCirculation · 2026Article
- Integrative multi-omics analysis reveals lipid/metabolite dysregulation and temporal decoupling in disease progression.Scientific reports · 2026Article
- Tissue-Resident Macrophage in Inflammation and Cancer.MedComm · 2026Review
- The Role of Immunoresolvents in Atherosclerosis: A Mini-Review on Their Biology and Therapeutic Opportunities.Health science reports · 2026Article
- Targeting Inflammation in Atherosclerosis: Mechanistic Rationale, Clinical Trials, and Regulatory Considerations.Reviews in cardiovascular medicine · 2026Review
- Cell apoptosis in ischemic stroke: Focus on lipid metabolism.Neural regeneration research · 2026Article
- Pediatric Critical Illness, Immunometabolism and Cardiovascular Risk: A Narrative Review.Minerva pediatrics · 2026Article
- Exploring the nexus: Clinical and physiological correlation between cardiovascular disease and colorectal cancer.Experimental physiology · 2026Review
- Macrophage efferocytosis in cardiovascular disease: mechanisms and therapeutic implications.ImmunoHorizons · 2026Review
- Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.Molecular biomedicine · 2026Review
- From anti-inflammation to pro-resolution: a new paradigm for specialized pro-resolving mediators in regulating neuroinflammation and repair after cerebral ischemia-reperfusion.Frontiers in immunology · 2026Review
208 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Gabrielle FredmanDepartment of Anesthesiology, Perioperative and Pain Medicine, Departments of Medicine, Pathology &Cell Biology, and Physiology, Columbia University Medical Center, 630 West 168th Street, New York, New York 10032, USA.
Jason HellmannDepartment of Anesthesiology, Perioperative and Pain Medicine, The Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Jonathan D ProtoDepartment of Anesthesiology, Perioperative and Pain Medicine, Departments of Medicine, Pathology &Cell Biology, and Physiology, Columbia University Medical Center, 630 West 168th Street, New York, New York 10032, USA.
George KuriakoseDepartment of Anesthesiology, Perioperative and Pain Medicine, Departments of Medicine, Pathology &Cell Biology, and Physiology, Columbia University Medical Center, 630 West 168th Street, New York, New York 10032, USA.
Romain A ColasDepartment of Anesthesiology, Perioperative and Pain Medicine, The Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Bernhard DorweilerDivision of Vascular Surgery, Department of Cardiothoracic and Vascular Surgery, University Medical Center of the Johannes Gutenberg University, Langenbeckstraße 1, Mainz D-55131, Germany.
E Sander ConnollyDepartment of Neurosurgery, Columbia University Medical Center, New York, New York 10032, USA.
Robert SolomonDepartment of Neurosurgery, Columbia University Medical Center, New York, New York 10032, USA.
David M JonesThe Department of Pathology, Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208, USA.
Eric J HeyerDepartment of Anesthesiology, Columbia University Medical Center, New York, New York 10032, USA.
Matthew SpiteDepartment of Anesthesiology, Perioperative and Pain Medicine, The Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Ira TabasDepartment of Anesthesiology, Perioperative and Pain Medicine, Departments of Medicine, Pathology &Cell Biology, and Physiology, Columbia University Medical Center, 630 West 168th Street, New York, New York 10032, USA.
Funding
TTC39B in obesity and atherosclerosisP01HL087123 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TALL, ALAN RICHARD · 2007 to 2022
$31.2MResolution Mechanisms in Acute Inflammation: Resolution PharmacologyP01GM095467 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2011 to 2020
$14.8MPOSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCHT32HL007343 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HENRY N GINSBERG, Muredach P Reilly · 1985 to 2026
$12.7MRole of Inflammation-Resolving Lipid Mediators In Ischemic RevascularizationR01HL106173 · NHLBI · UNIVERSITY OF LOUISVILLE · PI SPITE, MATTHEW R · 2011 to 2023
$5.7MThe Unfolded Protein Response in Sterol CytoxicityR01HL075662 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TABAS, IRA A · 2004 to 2017
$5.6MEnhancing Inflammation Resolution in Atherosclerosis via Targeted Nanoparticle-Mediated Delivery of BiologicsR01HL127464 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHI, JINJUN, TABAS, IRA A · 2016 to 2019
$3.0M"MerTK Cleavage and Signaling in Atherosclerosis"R01HL132412 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI TABAS, IRA A · 2016 to 2018
$1.5MSpecialized pro-resolving mediators in atherosclerosisR00HL119587 · NHLBI · ALBANY MEDICAL COLLEGE · PI FREDMAN, GABRIELLE · 2015 to 2017
$731kSpecialized pro-resolving mediators in atherosclerosisK99HL119587 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FREDMAN, GABRIELLE · 2013 to 2014
$216kNutrient excess alters resolution of inflammation in diabetes and obesityF32HL116186 · NHLBI · UNIVERSITY OF LOUISVILLE · PI HELLMANN, JASON L · 2013 to 2015
$159kNHLBI NIH HHS F32 HL116186NHLBI NIH HHS K99 HL119587NHLBI NIH HHS P01 HL087123NHLBI NIH HHS R00 HL119587NHLBI NIH HHS R01 HL075662NHLBI NIH HHS R01 HL106173NHLBI NIH HHS R01 HL127464NHLBI NIH HHS R01 HL132412NHLBI NIH HHS T32 HL007343NIGMS NIH HHS P01 GM095467
Abstract
Chronic unresolved inflammation plays a causal role in the development of advanced atherosclerosis, but the mechanisms that prevent resolution in atherosclerosis remain unclear. Here, we use targeted mass spectrometry to identify specialized pro-resolving lipid mediators (SPM) in histologically-defined stable and vulnerable regions of human carotid atherosclerotic plaques. The levels of SPMs, particularly resolvin D1 (RvD1), and the ratio of SPMs to pro-inflammatory leukotriene B
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.